|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies. | Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 2 | Neurovascular ageing:transcriptomic readout and implications on therapeutic targeting in Alzheimer’s disease显示文摘Ageing is one of the greatest risk factors for neurodegenerative diseases.How the complex biological changes in ageing increase the brain’s susceptibility to neurodegeneration remains incompletely understood.Research into neurodegenerative disorders has shifted from a neuron-centric approach,to the contributing roles of age-related neurovascular and glial cell dysfunction. | Zhongqi Li Bonaventure Ip Vincent C.T.Mok Ho Ko | 2021 | Neural Regeneration Research2021，16，12： | 3 |
| 3 | Pandemic of the aging society—sporadic cerebral small vessel disease显示文摘Age-related sporadic cerebral small vessel disease(CSVD)has gained increasing attention over the past decades because of its increasing prevalence associated with an aging population.The widespread application of and advances in brain magnetic resonance imaging in recent decades have significantly increased researchers’understanding in the in vivo evolution of CSVD,its impact upon the brain,its risk factors,and the mechanisms that explain the various clinical manifestation associated with sporadic CSVD.In this review,we aimed to provide an update on the pathophysiology,risk factors,biomarkers,and the determinants and spectrum of the clinical manifestation of sporadic CSVD. | Alexander Yuk Lun Lau Bonaventure Yiu Ming Ip Ho Ko Bonnie Yin Ka Lam Lin Shi Karen Ka Yan Ma Lisa Wing Chi Au Yannie Oi Yan Soo Thomas Wai Hong Leung Adrian Wong Vincent Chung Tong Mok | 2021 | Chinese Medical Journal2021，，2： | 3 |
| 4 | HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma显示文摘 | Man–Fung Yuen Danny Ka–Ho Wong James Fung Philip Ip David But Ivan Hung Kevin Lau John Chi–Hang Yuen Ching–Lung Lai | 2008 | Gastroenterology2008，，4： | 2 |
| 5 | Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment显示文摘 | Grace Lai–Hung Wong Henry Lik–Yuen Chan Hoi–Yun Chan Pete Chi–Hang Tse Yee–Kit Tse Christy Wing–Hin Mak Stanley King–Yeung Lee Zoe Man–Yi Ip Andrew Ting–Ho Lam Henry Wing–Hang Iu Joyce May–Sum Leung Vincent Wai–Sun Wong | 2013 | Gastroenterology2013，，5： | 2 |
| 6 | Anti–Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema显示文摘 | Allen C. Ho Ingrid U. Scott Stephen J. Kim Gary C. Brown Melissa M. Brown Michael S. Ip Franco M. Recchia | 2012 | Ophthalmology2012，，10： | 2 |
| 7 | Risk stratification in symptomatic intracranial atherosclerotic disease with conventional vascular risk factors and cerebral haemodynamics显示文摘Background and purpose Symptomatic intracranial atherosclerotic stenosis(sICAS)is associated with a considerable risk of recurrent stroke despite contemporarily optimal medical treatment.Severity of luminal stenosis in sICAS and its haemodynamic significance quantified with computational fluid dynamics(CFD)models were associated with the risk of stroke recurrence.We aimed to develop and compare stroke risk prediction nomograms in sICAS,based on vascular risk factors and these metrics.Methods Patients with 50%-99%sICAS confirmed in CT angiography(CTA)were enrolled.Conventional vascular risk factors were collected.Severity of luminal stenosis in sICAS was dichotomised as moderate(50%-69%)and severe(70%-99%).Translesional pressure ratio(PR)and wall shear stress ratio(WSSR)were quantified via CTA-based CFD modelling;the haemodynamic status of sICAS was classified as normal(normal PR&WSSR),intermediate(otherwise)and abnormal(abnormal PR&WSSR).All patients received guideline-recommended medical treatment.We developed and compared performance of nomograms composed of these variables and independent predictors identified in multivariate logistic regression,in predicting the primary outcome,recurrent ischaemic stroke in the same territory(SIT)within 1 year.Results Among 245 sICAS patients,20(8.2%)had SIT.The D2H2A nomogram,incorporating diabetes,dyslipidaemia,haemodynamic status of sICAS,hypertension and age≥50 years,showed good calibration(P for Hosmer-Lemeshow test=0.560)and discrimination(C-statistic 0.73,95%CI 0.60 to 0.85).It also had better performance in risk reclassification and provided larger net benefits in decision curve analysis,compared with nomograms composed of conventional vascular risk factors only,and plus the severity of luminal stenosis in sICAS.Sensitivity analysis in patients with anterior-circulation sICAS showed similar results.Conclusions The D2H2A nomogram,incorporating conventional vascular risk factors and the haemodynamic significance of sICAS as assessed in CFD models,could be a useful tool to stratify sICAS patients for the risk of recurrent stroke under contemporarily optimal medical treatment. | Xuan Tian Hui Fang Linfang Lan Hing Lung Ip Jill Abrigo Haipeng Liu Lina Zheng Florence S Y Fan Sze Ho Ma Bonaventure Ip Bo Song Yuming Xu Jingwei Li Bing Zhang Yun Xu Yannie O Y Soo Vincent Mok Ka Sing Wong Thomas W Leung Xinyi Leng | 2023 | Stroke & Vascular Neurology2023，8，1： | 2 |
| 8 | High-performance liquid chromatographic method for the simuhanous detection of the adulteration of cereal flours with melamine and relatedtriazine by-products ammeline,ammelide, and cyanuric acid显示文摘 | EHLING S TEFERA S HO IP | 2007 | Food Additives and Contaminants2007，24，12： | 1 |
| 9 | Serum leptin and vascular risk factors in obstructive sleep apnea显示文摘 | Ip MS Lam KS Ho C | 2000 | Chest2000，118，： | 1 |
| 10 | Serum leptin and vascular risk factors in obstructive sleep apnea显示文摘 | Ip MS Lam KS Ho C | 2000 | Chest2000，，118： | 1 |
| 11 | Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis显示文摘 | Grace Lai‐Hung Wong Henry Lik‐Yuen Chan Christy Wing‐Hin Mak Stanley King‐Yeung Lee Zoe Man‐Yi Ip Andrew Ting‐Ho Lam Henry Wing‐Hang Iu Joyce May‐Sum Leung Jennifer Wing‐Yan Lai Angeline Oi‐Shan Lo Hoi‐Yun Chan Vincent Wai‐Sun Wong | 2013 | Hepatology2013，，5： | 1 |
| 12 | Modulating effects of mannose-binding lectin genotype on arterial stiffness in children after Kawasaki disease显示文摘 | Cheung YF Ho MH Ip WK | 2004 | Pediatr Res2004，56，4： | 1 |
| 13 | Serum leptin and vascular risk factors in obstructive sleep apnea显示文摘 | Ip MS Lain KS Ho C | 2000 | Chest2000，118，3： | 1 |
| 14 | Serum leptin and vascular risk factors in obstructive sleep apnea 显示文摘 | Ip MS Lam KS Ho C | 2000 | Chest2000，118，3： | 1 |
| 15 | Leptin and vascular risk in obstructive sleep apnea显示文摘 | Ip MS Lam KS Ho C | 2000 | 118(3) :580-5862000，118，3： | 1 |
| 16 | The effect of Pseudomonas aerugino- sa infection on clinical parameters in steady-state bronchiectasis 显示文摘 | Ho P L Chin1 K N Ip M S | 1998 | Chest1998，114，6： | 1 |
| 17 | Serum leptin and vascular risk factors in obstructive sleep apnea显示文摘 | IP M S LAM K S HO C | 2000 | Chest2000，，11： | 1 |
| 18 | High Performance Liquid Chromatographic Method for the Simultaneous Detection of the Adulteration of Cereal Flours with Melamine and Related Triazine Byproducts Ammetine, Ammehde, and Cyanuric Acid 显示文摘 | EHLING S TEFERA S HO IP | 2007 | Food Addit Contam2007，24，： | 1 |
| 19 | Serum leptin and vascular risk factors in obstructive sleep apnea显示文摘 | Ip S Lamn K Ho C | 2000 | Chest2000，118，： | 1 |
| 20 | Serum leptin and vascular risk factors in obstructive sleep apnea 显示文摘 | Ip MS Lam KS Ho C | 2000 | Chest2000，118，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员